Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 129,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at twitter.com/novartis.
POSTED
06-09-14
The Novartis Foundation for Sustainable Development and Netherlands Leprosy Relief (NLR) today announced their collaboration with national leprosy programs and other International Federation of Anti-Leprosy Associations (ILEP) partners to interrupt transmission of leprosy. In pilot sites of sever...
POSTED
04-07-14
Novartis announced today that two million treatments of its pediatric antimalarial are arriving in Zambia thanks to the ongoing efforts of the company in collaboration with Malaria No More’s Power of One campaign. Zambia is the first beneficiary country of this campaign sponsored by Novartis. One...
POSTED
04-07-14
Novartis a annoncé aujourd'hui que deux millions de traitements de son antipaludique pédiatrique arrivent en Zambie grâce aux efforts actuels de la société, en collaboration avec la campagne Power of One de Malaria No More. La Zambie est le premier pays à bénéficier de cette campagne parrainée pa...
POSTED
04-07-14
Novartis hat heute angekündigt, dass durch die fortlaufende Zusammenarbeit mit der «Power of One»-Kampagne von Malaria No More zwei Millionen Behandlungseinheiten ihres pädiatrischen Malariamedikaments in Sambia bereitstehen werden. Sambia ist das erste Land, das von der von Novartis geförderten ...
POSTED
12-05-13
Today, Novartis senior executives gather in Basel, Switzerland for the first-ever Novartis Africa Day, to review the company’s innovative work in Africa, including growing commercial activity, novel approaches to expand access to high-quality, affordable medicines, local talent development and th...
POSTED
12-05-13
Heute treffen sich Führungsverantwortliche von Novartis in Basel, Schweiz, für den ersten Novartis Africa Day. Sie werden dort die innovative Arbeit des Unternehmens in Afrika prüfen, insbesondere die wachsenden kommerziellen Aktivitäten, neuartige Ansätze für einen besseren Zugang zu hochwertige...
POSTED
12-05-13
Aujourd’hui, les cadres dirigeants de Novartis se réunissent à Bâle, en Suisse, à l’occasion du premier « Novartis Africa Day ». Ils passeront en revue le travail mené par l’entreprise en Afrique, notamment l’activité commerciale croissante, les approches innovantes visant à étendre l’accès à des...
POSTED
11-29-13
Today’s symposium of the Novartis Foundation for Sustainable Development (NFSD) convenes experts to discuss “What does it take to eliminate a disease?” Drawing lessons from previous successful disease control programs, the symposium speakers discuss innovative approaches and advocate for new coor...
POSTED
11-29-13
Am heutigen Symposium der Novartis Stiftung für Nachhaltige Entwicklung (NFSD) diskutieren Experten über das Thema „Wie eliminiert man eine Krankheit?“ Ausgehend von Erfahrungen aus früheren erfolgreichen Programmen zur Krankheitsbekämpfung stellen die Referenten innovative Ansätze vor und treten...
POSTED
11-29-13
Le symposium de ce jour organisé par la Fondation Novartis pour un Développement Durable réunit des experts autour de la question suivante : « Comment éliminer une maladie ? » Tirant les enseignements de précédents programmes efficaces de lutte contre certaines maladies, les intervenants du sympo...